Approvals (Drugs@FDA)

UPTRAVI

ACTELION · SELEXIPAG

NDA207947Drug (NDA)Prescription
Open FDA's page for this record
Application number
NDA207947
Sponsor name
ACTELION
Submissions
  1. Submission type
    SUPPL
    Submission number
    8
    Submission status
    AP
    Submission status date
    20210130
    Review priority
    STANDARD
    Submission class code
    EFFICACY
    Submission class code description
    Efficacy
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      66041
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207947s008lbl.pdf
      Date
      20210201
      Type
      Label
    2. ID
      66048
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/207947Orig1s008ltr.pdf
      Date
      20210201
      Type
      Letter
  2. Submission type
    SUPPL
    Submission number
    10
    Submission status
    AP
    Submission status date
    20210819
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      68426
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207947s010lbl.pdf
      Date
      20210820
      Type
      Label
    2. ID
      68447
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/207947Orig1s010ltr.pdf
      Date
      20210824
      Type
      Letter
  3. Submission type
    SUPPL
    Submission number
    15
    Submission status
    AP
    Submission status date
    20260523
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      86051
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/207947Orig1s014; s015; 214275Orig1s002ltr.pdf
      Date
      20260527
      Type
      Letter
    2. ID
      86127
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/207947Orig1s014,s015;214275Orig1s002lbl.pdf
      Date
      20260911
      Type
      Label
  4. Submission type
    SUPPL
    Submission number
    9
    Submission status
    AP
    Submission status date
    20211025
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      69114
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/207947Orig1s009ltr.pdf
      Date
      20211026
      Type
      Letter
    2. ID
      69121
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207947s009lbl.pdf
      Date
      20211026
      Type
      Label
  5. Submission type
    SUPPL
    Submission number
    7
    Submission status
    AP
    Submission status date
    20190904
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      59914
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/207947Orig1s007ltr.pdf
      Date
      20190905
      Type
      Letter
    2. ID
      59920
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207947s007lbl.pdf
      Date
      20190905
      Type
      Label
  6. Submission type
    SUPPL
    Submission number
    5
    Submission status
    AP
    Submission status date
    20171220
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      50845
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207947s005lbl.pdf
      Date
      20171222
      Type
      Label
    2. ID
      50906
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/207947Orig1s005ltr.pdf
      Date
      20171227
      Type
      Letter
  7. Submission type
    SUPPL
    Submission number
    3
    Submission status
    AP
    Submission status date
    20170928
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      49881
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207947s003lbl.pdf
      Date
      20170929
      Type
      Label
    2. ID
      49895
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/207947Orig1s003ltr.pdf
      Date
      20170929
      Type
      Letter
  8. Submission type
    SUPPL
    Submission number
    1
    Submission status
    AP
    Submission status date
    20170721
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      49054
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207947s001lbl.pdf
      Date
      20170725
      Type
      Label
    2. ID
      49078
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/207947Orig1s001ltr.pdf
      Date
      20170725
      Type
      Letter
  9. Submission type
    ORIG
    Submission number
    1
    Submission status
    AP
    Submission status date
    20151221
    Review priority
    STANDARD
    Submission class code
    TYPE 1
    Submission class code description
    Type 1 - New Molecular Entity
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      19976
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/2015/207947s000lbl.pdf
      Date
      20151222
      Type
      Label
    2. ID
      23043
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000TOC.html
      Date
      20160128
      Type
      Review
    3. ID
      24529
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000SumR.pdf
      Date
      20160128
      Type
      Summary Review
    4. ID
      32866
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207947Orig1s000ltr.pdf
      Date
      20151222
      Type
      Letter
  10. Submission type
    SUPPL
    Submission number
    14
    Submission status
    AP
    Submission status date
    20260523
    Review priority
    PRIORITY
    Submission class code
    EFFICACY
    Submission class code description
    Efficacy
    Submission property type
    1. Code
      Orphan
    Application docs
    1. ID
      86050
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/207947Orig1s014; s015; 214275Orig1s002ltr.pdf
      Date
      20260527
      Type
      Letter
    2. ID
      86128
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/207947Orig1s014,s015;214275Orig1s002lbl.pdf
      Date
      20260911
      Type
      Label
Products
  1. Product number
    001
    Reference drug
    Yes
    Brand name
    UPTRAVI
    Reference standard
    No
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Te code
    AB
    Active ingredients
    1. Name
      SELEXIPAG
      Strength
      0.2MG
  2. Product number
    008
    Reference drug
    Yes
    Brand name
    UPTRAVI
    Reference standard
    No
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Te code
    AB
    Active ingredients
    1. Name
      SELEXIPAG
      Strength
      1.6MG
  3. Product number
    006
    Reference drug
    Yes
    Brand name
    UPTRAVI
    Reference standard
    No
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Te code
    AB
    Active ingredients
    1. Name
      SELEXIPAG
      Strength
      1.2MG
  4. Product number
    004
    Reference drug
    Yes
    Brand name
    UPTRAVI
    Reference standard
    No
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Te code
    AB
    Active ingredients
    1. Name
      SELEXIPAG
      Strength
      0.8MG
  5. Product number
    010
    Reference drug
    Yes
    Brand name
    UPTRAVI
    Reference standard
    No
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Active ingredients
    1. Name
      SELEXIPAG
      Strength
      0.1MG
  6. Product number
    002
    Reference drug
    Yes
    Brand name
    UPTRAVI
    Reference standard
    Yes
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Te code
    AB
    Active ingredients
    1. Name
      SELEXIPAG
      Strength
      0.4MG
  7. Product number
    007
    Reference drug
    Yes
    Brand name
    UPTRAVI
    Reference standard
    No
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Te code
    AB
    Active ingredients
    1. Name
      SELEXIPAG
      Strength
      1.4MG
  8. Product number
    005
    Reference drug
    Yes
    Brand name
    UPTRAVI
    Reference standard
    No
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Te code
    AB
    Active ingredients
    1. Name
      SELEXIPAG
      Strength
      1MG
  9. Product number
    011
    Reference drug
    Yes
    Brand name
    UPTRAVI
    Reference standard
    No
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Active ingredients
    1. Name
      SELEXIPAG
      Strength
      0.15MG
  10. Product number
    003
    Reference drug
    Yes
    Brand name
    UPTRAVI
    Reference standard
    No
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Te code
    AB
    Active ingredients
    1. Name
      SELEXIPAG
      Strength
      0.6MG
Harmonized identifiers (openFDA)
Application number
NDA207947
Brand name
UPTRAVI, UPTRAVI TITRATION PACK
Generic name
SELEXIPAG
Manufacturer name
Actelion Pharmaceuticals US, Inc.
Product NDC
66215-602, 66215-604, 66215-606, 66215-608, 66215-610, 66215-612, 66215-614, 66215-616, 66215-628, 66215-718, 66215-910, 66215-915
Product type
HUMAN PRESCRIPTION DRUG
Route
ORAL
Substance name
SELEXIPAG
RxCUI
1729007, 1729013, 1729027, 1729029, 1729031, 1729033, 1729045, 1729047, 1729051, 1729053, 1729055, 1729057, 1729059, 1729061, 1729063, 1729065, 1729075, 1729076, 2565271, 2565275, 2744282, 2744284, 2744286, 2744288
SPL ID
7c54a125-9778-41f5-b92c-181711e22e06
SPL set ID
a7a23b87-f892-4e2c-8e2e-ebf841220f90
Package NDC
66215-602-06, 66215-602-14, 66215-604-06, 66215-606-06, 66215-608-06, 66215-610-06, 66215-612-06, 66215-614-06, 66215-616-06, 66215-628-20, 66215-718-01, 66215-910-14, 66215-915-14
Nui
N0000192339, N0000020068
Pharm class epc
Prostacyclin Receptor Agonist [EPC]
Pharm class moa
Prostacyclin Receptor Agonists [MoA]
UNII
5EXC0E384L
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.